Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., Horbinski, C., Junck, L., Kaley, T., Kumthekar, P., Loeffler, J. S., Mrugala, M. M., Nagpal, S., Pandey, M., Parney, I., Peters, K., Puduvalli, V. K., Robins, I., Rockhill, J., Rusthoven, C., Shonka, N., Shrieve, D. C., Swinnen, L. J., Weiss, S., Wen, P. Y., Willmarth, N. E., Bergman, M. A., Darlow, S. D. 2020; 18 (11): 1537–70

Abstract

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of CNS cancers. Integrated histopathologic and molecular characterization of brain tumors such as gliomas should be standard practice. This article describes NCCN Guidelines recommendations for WHO grade I, II, III, and IV gliomas. Treatment of brain metastases, the most common intracranial tumors in adults, is also described.

View details for DOI 10.6004/jnccn.2020.0052

View details for PubMedID 33152694